Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms.

Cicconi P, Bini T, Barassi A, Casana M, Turri O, Pateri F, Marchetti GC, Biondi ML, d'Eril GM, d'Arminio Manforte A.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e96-7. doi: 10.1097/QAI.0b013e318203e7e7. No abstract available.


Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

Ferraris L, Viganò O, Peri A, Tarkowski M, Milani G, Bonora S, Adorni F, Gervasoni C, Clementi E, Di Perri G, Galli M, Riva A.

J Antimicrob Chemother. 2012 Sep;67(9):2236-42. doi: 10.1093/jac/dks175. Epub 2012 Jun 2.


Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.

Park WB, Choe PG, Song KH, Jeon JH, Park SW, Kim HB, Kim NJ, Oh MD, Choe KW.

Clin Infect Dis. 2010 Jul 1;51(1):101-6. doi: 10.1086/653427.


Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.

Culley CL, Kiang TK, Gilchrist SE, Ensom MH.

Ann Pharmacother. 2013 Apr;47(4):561-72. doi: 10.1345/aph.1R550. Epub 2013 Apr 2. Review.


Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1287-92. doi: 10.1089/AID.2013.0002. Epub 2013 Jul 19.


High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.

Panagopoulos P, Paraskevis D, Katsarolis I, Sypsa V, Detsika M, Protopapas K, Antoniadou A, Papadopoulos A, Petrikkos G, Hatzakis A.

Int J STD AIDS. 2014 Oct;25(12):860-5. doi: 10.1177/0956462414523259. Epub 2014 Feb 10.


Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.

Lozano R, Domeque N, Apesteguia AF.

J Clin Pharmacol. 2014 Feb;54(2):161-7. doi: 10.1002/jcph.234. Epub 2013 Dec 2.


Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.

Choe PG, Park WB, Song JS, Kim NH, Song KH, Park SW, Kim HB, Kim NJ, Oh MD.

J Korean Med Sci. 2010 Oct;25(10):1427-30. doi: 10.3346/jkms.2010.25.10.1427. Epub 2010 Sep 17.


Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.

Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, Soriano V.

AIDS. 2007 Jan 2;21(1):41-6.


Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.

Turatti L, Sprinz E, Lazzaretti RK, Kuhmmer R, Agnes G, Silveira JM, Basso RP, Pinheiro CA, Silveira MF, de Almeida S, Ribeiro JP, Mattevi VS.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1015-8. doi: 10.1089/AID.2011.0261. Epub 2012 May 3.


Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.

Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.

Clin Ther. 2008 Oct;30(10):1794-805. doi: 10.1016/j.clinthera.2008.10.006.


Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.

Avihingsanon A, Tongkobpetch S, Kerr SJ, Punyawudho B, Suphapeetiporn K, Gorowara M, Ruxrungtham K, Shotelersuk V.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7. doi: 10.1097/QAI.0000000000000540. No abstract available.


Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Rodríguez Nóvoa S, Barreiro P, Rendón A, Barrios A, Corral A, Jiménez-Nacher I, González-Lahoz J, Soriano V.

Clin Infect Dis. 2006 Jan 15;42(2):291-5. Epub 2005 Dec 8.


Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.

Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, Strassburg CP.

Hepatology. 2006 Nov;44(5):1324-32.


Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.

Lopardo G, Bissio E, Espinola L, Gallego P, Stambullian M, Gadano A.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):456-60. doi: 10.1089/aid.2012.0232. Epub 2012 Oct 31.


Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.

Morello J, Alvarez E, Cuenca L, Vispo E, González-Lahoz J, Soriano V, Rodríguez-Nóvoa S.

AIDS Res Hum Retroviruses. 2011 Oct;27(10):1043-5. doi: 10.1089/AID.2011.0019. Epub 2011 Mar 23.


The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score.

Rodriguez JM, Hermida JM, Casado JL, Quereda C, Moreno A, Dronda F, Hernandez-Novoa B, Rodriguez MA, Perez-Elias MJ, Moreno S.

AIDS. 2011 Apr 24;25(7):1006-9. doi: 10.1097/QAD.0b013e3283466f85.


Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

Estévez JA, Moltó J, Tuneu L, Cedeño S, Antonijoan RM, Mangues MA, Clotet B, Domingo P, Puntes M, Barbanoj MJ, Valle M.

J Antimicrob Chemother. 2012 Aug;67(8):2013-9. doi: 10.1093/jac/dks152. Epub 2012 May 7.


Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S.

J Antimicrob Chemother. 2009 Nov;64(5):1071-9. doi: 10.1093/jac/dkp317. Epub 2009 Aug 26.

Items per page

Supplemental Content

Write to the Help Desk